Furukawa Taku, Lankadeva Yugeesh R, Baldwin Ian C, Ow Pei Chen Connie, Hood Sally, Daali Youssef, Schneider Antoine, Decosterd Laurent A, May Clive N, Bellomo Rinaldo
Preclinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia,
Preclinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
Blood Purif. 2025 Feb 18:1-5. doi: 10.1159/000544770.
Hemoadsorption has emerged as a potential intervention for the removal of ticagrelor. We aimed to evaluate the efficacy of the HA380 hemoadsorption cartridge for this purpose.
Six healthy adult sheep received 270 mg of ticagrelor via an orogastric tube, followed by hemoadsorption using a HA380 cartridge for a duration of 4 h. The sorbent-based removal ratio, clearance, and mass removal rate were assessed at multiple time points.
The HA380 cartridge achieved an initial sorbent-based removal ratio of 48.9% (SD 11.8) at 10 min, which declined rapidly to 2.66% (SD 18.5) at 120 min and 0.48% (SD 17.0) at 240 min. Clearance followed a similar trend, starting at 46.1 mL/min (SD 11.4) and decreasing to 0.08 mL/min (SD 16.8) at 240 min. The mass removal rate also dropped significantly over time, from 3.74 ng/min (SD 2.54) at 10 min to near zero at 120 and 240 min.
HA with the HA380 cartridge can achieve an early 50% adsorption level for ticagrelor. If frequently changed, the HA380 cartridge may serve as a potential option for ticagrelor removal, when clinically indicated.
血液吸附已成为一种去除替格瑞洛的潜在干预措施。我们旨在评估HA380血液吸附柱在此方面的疗效。
6只健康成年绵羊经口胃管给予270mg替格瑞洛，随后使用HA380柱进行4小时的血液吸附。在多个时间点评估基于吸附剂的清除率、清除量和质量清除率。
HA380柱在10分钟时基于吸附剂的初始清除率为48.9%（标准差11.8），在120分钟时迅速降至2.66%（标准差18.5），在240分钟时降至0.48%（标准差17.0）。清除量遵循类似趋势，起始为46.1mL/分钟（标准差11.4），在第240分钟时降至0.08mL/分钟（标准差16.8）。质量清除率也随时间显著下降，从10分钟时的3.74ng/分钟（标准差2.54）降至120分钟和240分钟时接近零。
使用HA380柱的血液吸附可使替格瑞洛早期达到50%的吸附水平。如果频繁更换，当有临床指征时，HA380柱可能是去除替格瑞洛的一种潜在选择。
